Lv1
86 积分 2021-04-14 加入
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
1天前
已完结
Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma
6个月前
已完结
Efficacy of docetaxel addition to next‐generation androgen receptor‐axis‐targeted therapies and androgen deprivation therapy in metastatic hormone‐sensitive prostate cancer: A tumor volume‐specific analysis
6个月前
已完结
Targeted therapy in acute myeloid leukemia: resistance and overcoming strategy
6个月前
已完结
Meta‐analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma
7个月前
已完结
Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial
7个月前
已完结
EZH2 regulatory roles in cancer immunity and immunotherapy
7个月前
已完结
Synergistic antitumor effect of combined EZH2 and DOT1L inhibition in B-cell lymphoma
7个月前
已完结
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
7个月前
已完结
皖公网安备34019202002308
